Bio-Techne(US:TECH)2026-03-10 13:42Bio-Techne 2026 Conference Summary Company Overview - Company: Bio-Techne (NasdaqGS: TECH) - Industry: Life Science Tools and Diagnostics Key Market Insights Pharma Market - Pharma represents approximately 30% of Bio-Techne's revenue - Exited December quarter with low double-digit growth, marking the fifth consecutive quarter of double-digit growth [6][7] - Concerns regarding MFN pricing and tariffs were alleviated, leading to continued strong performance in large pharma [7][8] Biotech Market - Biotech accounts for about 20% of revenue - Exited Q2 with mid-single-digit declines in biotech, which is seen as a positive outcome given a 40% decline in biotech funding in the first half of 2025 [9][12] - Recent funding trends show signs of recovery, with funding increasing by over 90% exiting December [14][15] - M&A activity among large pharma acquiring biotechs is increasing, indicating a positive outlook for new investors [16] Academic Market - Academic market contributes a little over 20% of global revenues, split evenly between Europe and the U.S. - European academic market shows low- to mid-single-digit growth, while U.S. academic market has stabilized with low single-digit declines [24][28] - Recent approval of a 1% increase in NIH funding is a positive development, although the impact on spending is still uncertain [32][36] Asia Market - Asia accounts for 16%-17% of revenue, with half from China - China has seen three consecutive quarters of growth, with double-digit growth in the rest of Asia [41][45] - Optimism is returning in China regarding government funding for biotechs, with increased licensing activity from pharma [62] Financial Guidance - For fiscal year 2026, Bio-Techne expects to exit Q4 with mid-single-digit growth [66] - Concerns about timing of recovery in funding translating into spending, with historical lag of 2-3 quarters noted [79][81] - Anticipated headwinds from two large GMP customers, which have been significant contributors to revenue, are expected to lessen in Q4 [88][91] Growth Drivers - The cell therapy franchise has shown resilience, with 30% growth among remaining customers excluding two large GMP customers [102] - Over 80 customers are in clinical trials, indicating a robust pipeline [104] - The company expects a floor of 20% growth in a normal market for the remaining customer base [121] M&A Strategy - Bio-Techne remains committed to M&A as a priority for capital deployment, focusing on quality over quantity in potential acquisitions [141][156] - Areas of interest include cell therapy and organoids, with a belief that these sectors will continue to grow significantly [157] AI and Future Outlook - AI is viewed as a significant enhancement for the industry, with expectations that it will drive growth in life science tools over the next several years [175][180] - The company is actively using AI to develop next-generation proteins, which are expected to be a key growth area [175][189] Margin Expansion - Bio-Techne anticipates 100 basis points margin expansion in 2026, driven by growth in differentiated products [196][199] - Historical growth rates suggest that mid-single-digit to high single-digit growth should yield at least 50 basis points in margin expansion [199][203] Conclusion - Bio-Techne is positioned for growth across various markets, with positive trends in pharma, biotech, and academic sectors. The company is focused on strategic M&A, leveraging AI for innovation, and maintaining margin expansion through differentiated product offerings.